Rein therapeutics announces publication of new translational data in iscience on company's novel therapy for idiopathic pulmonary fibrosis

Austin, texas, sept. 17, 2025 (globe newswire) -- rein therapeutics ("rein") (nasdaq: rntx), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced the publication of novel data on its lead drug candidate, lti-03, in iscience, a peer-reviewed, open-access journal published by cell press.
RNTX Ratings Summary
RNTX Quant Ranking